| Advertisements |
Total number |
54 |
44 |
134 |
236 |
206 |
|
Mean number of pages per advertisement |
1.0 |
1 |
1.1 |
1.2 |
1.0 |
|
(SD) |
(0.1) |
– |
(0.3) |
(0.4) |
(0.1) |
|
Minimum and maximum numbers of pages |
1.0 to 2.0 |
1 to 1 |
0.5 to 2.0 |
0.5 to 2.0 |
0.5 to 2.0 |
| Calls for enrollment ofpatients in registration trials |
Phase I, n (%) |
0 (0.0) |
0 (0.0) |
5 (3.7) |
0 (0.0) |
0 (0.0) |
|
Phase II, n (%) |
21 (38.9) |
15 (34.1) |
42 (31.3) |
29 (12.3) |
46 (22.3) |
|
Phase III, n (%) |
16 (29.6) |
14 (31.8) |
77 (57.5) |
201 (85.2) |
150 (72.8) |
|
Unknown, n (%) |
17 (31.5) |
15 (34.1) |
10 ′7.5) |
6 (2.5) |
10 (4.9) |
| Explanation of trial design |
Randomization, n (%) |
18 (33.3) |
17 (38.6) |
79 (59.0) |
218 (92.4) |
158 (76.7) |
|
Blinding, n (%) |
14 (25.9) |
12 (27.3) |
64 (47.8) |
138 (58.5) |
75 (36.4) |
|
Multiregionality, n (%) |
2 (3.7) |
0 (0.0) |
41 (30.6) |
124 (52.5) |
56 (27.2) |
|
Brief summary of trial, n (%) |
28 (51.9) |
16 (36.4) |
104 (77.6) |
188 (79.7) |
145 (70.4) |
|
Primary endpoint, n (%) |
1 (1.9) |
16 (36.4) |
109 (81.3) |
199 (84.3) |
138 (67.0) |
|
Secondary endpoint, n (%) |
1 (1.9) |
9 (20.5) |
32 (23.9) |
28 (11.9) |
57 (27.7) |
|
Sample size, n (%) |
5 (9.3) |
9 (20.5) |
37 (27.6) |
127 (53.8) |
105 (51.0) |
|
Mechanism of action of investigationalagent, n (%) |
1 (1.9) |
0 (.0) |
25 (18.7) |
38 (16.1) |
56 (27.2) |
|
Code number of clinical trialregistration, n (%) |
6 (11.1) |
9 (20.5) |
19 (14.2) |
42 (17.8) |
74 (35.9) |
|
Main eligibility criteria |
49 (90.7) |
36 (81.8) |
119 (88.8) |
210 (89.0) |
127 (61.7) |
|
Cautionary statement of disapprovedindication, n (%) |
0 (0.0) |
0 (0.0) |
89 (66.4) |
173 (73.3) |
134 (65.1) |
